In this study, we demonstrate that IDH1-mutant AML cells are markedly more sensitive to cuproptosis induced by the copper ionophore elesclomol (ES), compared to their wild-type counterparts...In vivo experiments confirm that ES more effectively suppresses tumor growth in IDH1-mutant xenografts. These findings uncover a copper-dependent metabolic vulnerability and provide a rationale for exploiting cuproptosis as a therapeutic strategy in IDH1-mutant AML.

The PS exhibits absorption at 665 nm (in vivo) and shows desired pharmacokinetics with limited skin phototoxicity in patients, compared to FDA-approved Photofrin...Combination of COX-2 inhibition with PDT or with BCG-immunotherapy showed an improved rate of tumor cures. Hence, HPPH-PDT in combination with COX-2 inhibitors not only reduces the expression of COX-2, IL-6, VEGF, and PGE2 but also enhances long-term tumor cure.

This study highlights FINs as effective cuproptosis potentiators and suggests a novel combinatorial regimen that simultaneously targets cuproptosis and ferroptosis, offering dual antitumor and bone-protective benefits for OS therapy.

Knockdown of ZNF143/SAV1 signaling impaired the therapeutic effect of HWM, and treatment with verteporfin, pharmacological inhibition of YAP/TAZ, reversed the effects of knockdown of SAV1. Therefore, HWM might offer a potent strategy for managing TNBC effectively.

For the cuproptosis, Rh1 promoted the elesclomol-Cu (ES-Cu) or disulfiram-Cu induced proliferation inhibition. Finally, this work verified that Ginsenoside Rh1 promoted the cuproptosis and repressed the immune evasion of GC cells. In short, Ginsenoside Rh1 attenuated the ATP7A to potentiate the copper accumulation and cuproptosis, thereby alleviating cuproptosis-related immune evasion.

P1, N=9, Completed, Roswell Park Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Oct 2026 --> Oct 2025

P2, N=12, Not yet recruiting, Odense University Hospital

Consequently, cells switch from the tricarboxylic acid (TCA) cycle respiration to glycolysis, reducing sensitivity to the copper ionophore elesclomol (ES)...HBx-mediated repression of SIRT3 disrupts STEAP4 deacetylation and mitochondrial targeting, fostering metabolic reprogramming and evasion of copper-induced cell death. The results provide a pre-clinical rationale for copper-directed combination strategies in HBV-associated HCC.

Using elesclomol-copper complex treatment, a cuproptosis model in HCT116 and RKO CRC cell lines was established...Tumors with elevated EZH2-NEAT1 expression may be particularly sensitive to copper-based therapies. This study establishes EZH2-NEAT1 expression as a potential biomarker for patient selection in cuproptosis-based cancer treatment, though the concurrent effects on tumor migration highlight complex therapeutic considerations for combination treatment strategies.

Keyword and co-citation analyses revealed a thematic shift from foundational mechanistic studies toward prognostic modeling, copper ionophore exploration (e.g., elesclomol and disulfiram), immune-related analyses, and bioinformatics-driven patient stratification. The strong geographic concentration of publications and limited international collaboration highlight structural imbalances in knowledge production and the need for broader global validation. This bibliometric mapping clarifies the field's early developmental stage and identifies priorities for future research, including cross-regional collaboration, experimental standardization, and cautious advancement toward clinical application.

P1/2, N=52, Recruiting, Bold Therapeutics Inc.

P1/2, N=52, Recruiting, Bold Therapeutics Inc. | N=38 --> 52